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Background. Multiple sclerosis (MS) patients of African ancestry have a more aggressive disease course than white patients and
could be resistant to interferon-beta (INFB). Methods. We studied the impact of INFB in treatment-naive Afro-Caribbean (AC)
with clinically deﬁnite MS using our European Database for Multiple Sclerosis (EDMUS) (2003–2010). Main outcome measures
were annual relapse rate after 2 years of treatment, proportion of exacerbation-free subjects 48 weeks after initiating INFB, and
time to ﬁrst relapse. Results. 76 AC-MS (59F/17M) were identiﬁed. Annual relapse rate of 1.29 decreased to 0.83 (−35.6%) after
2 years of treatment. The proportion of relapse-free patients at 48 weeks was 46.2%. Median time to ﬁrst relapse was 52 weeks.
Conclusion. INFB is not strong enough to control AC-MS patients in many cases which is problematic in a population of worse
MS prognosis.
1.Introduction
Subjects of African ancestry have a more aggressive course of
multiple sclerosis (MS) than white patients [1–5]. In addi-
tion, they could be less responsive to interferon-beta (INFB)
than Caucasians [6]. We aimed to determine the eﬀect of
INFB in a large sample of Afro-Caribbean (AC) MS patients.
2.Methods
All MS patient visits at the Fort de France Department of
Neurology have been entered prospectively in the European
Database for Multiple Sclerosis (EDMUS) since 2003. Data
includedsex,ageatonset,dateofINFBinitiationanddiscon-
tinuation, type of INFB, date and characteristics of relapses,
and Expanded Disability Status Scale (EDSS) score. Patients
are seen when INFB is initiated, at months 1, 2, 3, and 6 and
then twice a year, as requested by French Drug Agency. Data
from patients with clinically deﬁnite MS [7] having received
INFB as ﬁrst-line therapy and for any length of time were
extracted from the Fort de France EDMUS database (August
31, 2010). Those with age between 18 and 55 years, EDSS of
0 to 5.5, and at least 2 relapses in the 2 previous years before
INFB-treatment initiation were eligible for the study. Data
taken in consideration were age at onset, disease duration at
the beginning of treatment, annualized relapse rate for the
2 years prior to INFB therapy and for the ﬁrst two years
on INFB therapy, and EDSS when treatment was initiated
as well as at 2 years of treatment. Patients who remained
free from relapses at 24 weeks, 48 weeks, and 104 weeks of
INFB therapy were identiﬁed. A Relapse was deﬁned as the
appearance of new neurological symptoms or worsening of
pre-existing symptoms lasting at least 24 hours, preceded by
30 days of clinical stability, accompanied by objective change
on examination (worsening of 0.5 point on the EDSS or 1.0
point on the motor, cerebellar, brainstem, or visual func-
tional system scores) in the absence of fever (pseudorelapse).
Relapses were treated with intravenous methylprednisolone.
Subjects who did not conﬁrm diagnosis of clinically deﬁnite
MS and patient who fulﬁlled revised diagnostic criteria for
neuromyelitis optica were excluded [8].
2.1. Statistical Analysis. Kaplan Meier curve was used to
assess median time to ﬁrst relapse and Log-rank test to
evaluate the eﬀect of categorical variables. The level of
statistical signiﬁcance was set at P<. 05. Statistical analysis
was conductedusing StatViewstatisticalversion5.0software.2 Multiple Sclerosis International
3.Results
We identiﬁed 76 AC-MS patients fulﬁlling inclusion criteria
(Table 1): 59 females and 17 males (sex ratio F/M: 3.5).
Of these, 50% received Betaseron (Shering AG, Berlin,
Germany) 8MIU every other day, 21.1% Rebif (Serono,
Geneva, Switzerland) 44-µg three times weekly, and 28,9%
Avonex (Biogen, Cambridge, Mass, USA) 30-µg each week.
The mean age at onset of MS was 30.1 years, and the mean
disease duration at initiation of INFB therapy was 4.7 years.
Mean duration of treatment was 38.3 months (median: 34).
In the two years preceding INFB therapy, mean number of
relapses was 2.3giving a mean annualized relapse rate of1.29
that decreased to 0.83 (−35.6%) after 2 years of treatment.
Mean EDSS at baseline was 2.52 (median 2.5) and slightly
increased to 2.66 at two years followup (P = .16).
Patients who remained free from relapses at 24 weeks,
48 weeks, and 104 weeks of INFB therapy were 66,6%,
46.2%, and 29.2%, respectively (7 relapse-free patients who
received treatment for < 6 months were excluded because
ap e r i o do f< 6 months of therapy would be too short to
evaluate a clinical treatment eﬀect). The median time to ﬁrst
relapse was 12 months (95% Conﬁdence Interval: 10.7–13.3
months). One variable trended to signiﬁcance was identiﬁed
to contributetoearly failure ofINFBtherapyin AC-MS:men
had a shorter time to ﬁrst relapse than women (11 months
versus 14 months; P = .08). Age at onset of MS, disease
duration,EDSSatbaseline,relapseratebeforetreatment,and
type of INFB did not contribute.
4.Discussion
InourobservationalcohortofAC-MSsubjects,mean disease
duration, mean age at ﬁrst symptom, and annualized mean
number of relapses 2 years before INFB reproduce inclusion
criteria of pivotal and head-to-head trials of INFB. INFB
therapy reduced the relapse rate by 35.6% in this series. This
is within the expected range of treatment (48 to 53%) eﬀects
reported in pivotal trials of INFB [9–11], but it may still
not good enough for most patients. The annualized rate of
relapses over 2 years remained high (0.83) for ours patients
treated with either INFB-1a or INFB-1b. By comparison,
the annualized relapse rate at end of two years study was
0.7 and 0.5 in INFB-1a and INFB-1b arms, respectively,
in INCOMIN trial [12], 0.54 and 0.65 in INFB-1a 44 µg
and INFB 30µg arms, respectively, in EVIDENCE trial [13],
and 0.61 in INFB-1a pivotal trial [11]. The proportion
of patients who remained relapse-free at 48 weeks after
initiating INFB therapy was 46.2%. Likewise, percentage of
relapse-free patients at two years (29.2%) in our cohort is
outside the range of INFB (32 to 51%) eﬀects in PRISMS
[10], INCOMIN trials [12]. Time to ﬁrst relapse was 12
months in our cohort, shorter to that observed in INFB-1a
44µg arm (13.5 months) of the EVIDENCE trial. However,
time to ﬁrst relapse was 47.3 weeks in INFB-1a pivotal trial
[11]. They are some of limitations to our observational
study. First, we are not able to discuss primary endpoint of
pivotal trials of INFB because there is no control group in
our study. Second, disease activity on MRI scans was not
Table 1: Demographic/clinical analysis of AC-MS, WA-MS, and
AA-MS of EVIDENCE study.
Clinical/demographic
Information
AC-MS
n = 76
WA-MS
(EVIDENCE)
n = 616
AA-MS
(EVIDENCE)
n = 36
Female, % 77.6 74.5 86.1
Mean age at ﬁrst
symptom, years
(range)
30.1
(14–50) 31.8 (18–55) 32.1 (18–55)
Mean disease
duration, years
(median)
4.7 (2) 6.9 5.6
Mean treatment
duration, weeks 153.2 62 62
Mean EDSS at
treatment (median) 2.52 (2.5) 2.3 2.8
Mean number of
relapses in the 2
previous years
(median)
2.3 (2) 2.6 2.5
%, relapse free at
48 weeks 46.2 57 47
available. Finally, we cannot exclude an overestimation of
relapses during INFB therapy by nonblinded neurologists.
However, our data showed a poorer response to INFB in
AC-MS patients concerning all secondary clinical endpoints
in pivotal and head-to-head trials of INFB. Furthermore,
our results reproduce those provided in Afro-American
(AA) MS by EVIDENCE post-hoc analysis. In this trial,
a similar proportion (47% versus 46.2%) of relapse-free
AA-MS patients after 48 weeks of treatment was observed
(Table 1). We only found a trend for male gender to predict
early INFB therapy failure. Others showed that in the setting
of daily MS practice, Caucasian INFB responders had an
older age, a higher relapse rate prior to treatment, and
longer disease duration at the time INFB was initiated
[14]. Poor beneﬁcial outcome of INFB therapy in people
of African ancestry has not been investigated but could
result either alone or in combination with development of
neutralizing antibodies against INFB or polymorphisms in
genes interplaying with INFB response such as glypicans
(GPC5), hyaluronan proteoglycan link protein (HAPLN1),
interferon receptors (INFAR1 and INFAR2), and MxA [15].
Given highly aggressive nature of disease in MS patients of
CA descent and suboptimal response to INFB, consideration
should be given to upgrading therapy to more aggressive
options (monoclonals antibodies or immunosuppressors)
early on in the disease course.
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